Three peer-reviewed case reports document fenbendazole-induced liver injury — all fully reversible after stopping. This guide covers the risk factors, a liver monitoring schedule, support supplements like milk thistle and TUDCA, and who should avoid fenbendazole entirely.

Colorectal, pancreatic, and liver cancers are among the most asked-about for fenbendazole. We review the AACR colorectal data, ferroptosis in 5-FU-resistant cancer, benzimidazole-gemcitabine pancreatic synergy, hepatocellular carcinoma findings, and key safety considerations.